Pursuant to the Agreement, Avicanna and Sunnybrook Hospital which is one of Canada’s leading hospitals and research centres have agreed to collaborate on the development of an education program to educate patients and train health care professionals about the RHO Phyto product formulary.
The growing demand for access to standardized cannabinoid medicine in the medical community, coupled with the advancement of cannabis access regulations permits Canadian hospitals with appropriate infrastructure to store and dispense qualified medical cannabis products such as the RHO Phyto offerings.
“This is an incredibly significant development for Avicanna as it validates our medical focus and credibility with the healthcare community.
“Patients have questions about and want access to plant-based cannabinoids, and that requires healthcare professionals to become knowledgeable about the use of cannabinoids for medical purposes,” said Carlo DeAngelis, pharmacist and researcher at Sunnybrook Hospital’s Odette Cancer Centre.
RHO Phyto is Avicanna’s unique formulary of products that are backed by scientific rigour and an evidence-based approach to meet the quality and consistency standards that patients and the medical community should expect of medical cannabis products.
Sunnybrook Health Sciences Centre is inventing the future of health care for the 1.2 million patients the hospital cares for each year through the dedication of its more than 10,000 staff and volunteers.
With ongoing studies on its derma-cosmetic and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception.
Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients.
Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to establish a complete cannabis consultation and dosing regimen, the ability of the Company and Sunnybrook to establish a gold standard of care for cannabinoid-based medicine by providing support and educating and training physicians, pharmacists and patients on the formulary of the RHO Phyto products, the likelihood that the Company’s and Sunnybrook’s education initiative will allow for a personalized medicine approach to track patient outcomes and promote the safe and consistent use of cannabinoid-based medicines, the ability of Sunnybrook to purchase the RHO Phyto products from Medical Cannabis by ShoppersTM.
Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .
The statements in this press release are made as of the date of this release.